Geoffrey Attardo first tried Prozac to treat his depression when he was doing postdoctoral research at Yale School of Public Health and was feeling the pressures of a new job in academia. Soon after he started, the colors around him seemed brighter, he had enough motivation to begin exercising more, and he felt hopeful for the first time in a long while. But about five months into the treatment, colors started dulling again and his energy waned. Increasing the dose didnt help.
He eventually switched to a similar antidepressant called Zoloft and has been on it for about 20 years, though it makes him emotionally numb and never completely got rid of the depression. It takes the edge off and keeps you from completely breaking down, he said, but its not really a great way to live.
Then this year, Attardo, who is 49, tried a new treatment for depression ketamine a drug long used as an anesthetic and that works through a different pathway in the brain than the traditional drugs hed taken. A few days after one of his first ketamine infusions, he found himself awake at 9 a.m., a time he usually slept long past, with much more energy than usual.
Patient responses like Attardos, after years of unsuccessful treatment with standard drugs, are spurring a gradual and, some would say, overdue shift in psychiatry toward a new way of thinking about depression, its causes, and therapies. The professions long embrace of the monoamine hypothesis the idea that depression primarily results from abnormal levels of neurotransmitter chemicals in the brain and that drugs can restore the proper balance is giving way to a more complex understanding and alternative treatments, from ketamine to psychedelics to magnetic stimulation.
The stubbornly high, and steadily increasing, rate of suicides in the U.S.is one factor driving the shift. In April, the National Institute of Mental Health (NIMH) awarded eight grants to test new ways to reduce suicidal thoughts and behaviors in a fast-acting manner, including ketamine and using magnets to activate parts of the brain.
Overall, an unofficial estimate shows the agencys funding for research involving novel antidepressants roughly doubled from $34.3 million in the 2007 fiscal year to $68.5 million in FY 2020, based on a search of the National Institutes of Health RePORTER database. A search for transcranial magnetic stimulation for depression reveals an estimated ninefold increase to $21.4 million over the same period.
Nolan Williams, a psychiatrist and neurologist at Stanford University, received one of the new grants as well as another from the NIMH to study magnetic stimulation in treatment-resistant depression. He said there is a push in the field to to think beyond the typical view of depression, and consider new treatments. Were enhancing [the monoamine] view to have a multilevel understanding of the problem, he said. Its about incorporating it into a deeper, more dynamic understanding [of depression].
NIMH Director Joshua Gordon told STAT the agency recognizes that new treatments for depression are needed and that it is funding research to explore the underlying biology beyond the monoamine hypothesis. When it comes to understanding depression, there are fewer and fewer questions of importance with regard to the monoamine systems, he said. He noted that in addition to federal funding, many startups and small companies are pursuing new treatments for depression.
Currently, almost all patients with depression are first treated with medications called selective serotonin reuptake inhibitors, a class of drugs that includes both Zoloft and Prozac. They increase the amount of the neurotransmitter serotonin in the brain, which controls mood, emotions, and cognition. Serotonin and two other neurotransmitters targeted by some antidepressants, norepinephrine and dopamine, are called monoamines because they contain one chemical group called an amine.
The entire thinking of the approach to treating depression is pretty much confined in that little box, said Lisa Harding, a psychiatrist at the Yale School of Medicine.
The monoamine hypothesis came about by serendipity. In the 1960s, doctors found that certain drugs, like iproniazid that was used to treat tuberculosis, had an unintended side effect: They messed with the levels of monoamine neurotransmitters and affected patients mood. The explanation for mental health disorders had previously eluded psychiatrists, so they were overjoyed to have a lead to follow.
The theories arose because of the actions of the drugs, said Phil Cowen, professor of psychopharmacology at University of Oxford who studies depression. In retrospect, its simplistic, but there wasnt really much else to go on.
Soon, clinicians realized that some observations didnt mesh with the hypothesis. Antidepressant drugs took weeks to improve the symptoms of depression, suggesting that the drugs may not be working through neurotransmitters exclusively. Then, psychiatrists found that many people, like Attardo, did not respond to monoamine antidepressants. About 1 out of every 3 patients with depression is diagnosed with treatment-resistant depression, meaning at least two antidepressants failed to improve their symptoms.
Even with these contradictions, doctors faithfully stuck by the hypothesis as the central dogma. The field got stuck in a cul-de-sac of just looking at [the same drugs], said Cowen.
Then a study done by researchers at Yale University in 2000 found that ketamine rapidly improved depression symptoms in seven patients. Although it was a small study, it opened the door for researchers to explore other potential treatments for depression.
Weve now got a completely different option for the treatment-resistant group, said Susannah Murphy, researcher at the University of Oxford who studies how to improve treatments for depression. The finding emboldened researchers to explore other drug targets and develop different therapies, she added: It put a lot more confidence back in new treatments.
Researchers are now exploring those new treatments and, in parallel, are seeking to advance the biological understanding of mental health disorders. In 2019, the FDA approved Spravato, a nasal spray of a version of ketamine called esketamine, for the treatment of adults with treatment-resistant depression. Studies have found that ketamine works through receptors for another neurotransmitter, glutamate, which is also dysregulated in depression. Glutamate and its receptors underlie a process called synaptic plasticity, in which brain connections strengthen or weaken. This supports the idea that changes in synaptic plasticity underlie depression and by targeting glutamate, ketamine could be reversing those changes.
Along with ketamine, other psychedelics, like psilocybin, have emerged as candidates for treatment-resistant depression. A small study published in the New England Journal of Medicine in April showed that psilocybin was as effective as a common antidepressant drug.
The psychedelic market is seen as so potentially lucrative that half a dozen companies in that space have gone public this year. Cybin, which has a psilocybin formulation in a Phase 2 clinical trial for major depression, started selling shares on the New York Stock Exchange last week, and five other psychedelics companies are already listed on the Nasdaq.
Psychedelics like psilocybin mostly activate receptors for serotonin, similar to the typical antidepressants. But studies show that psilocybin also can change levels of glutamate, suggesting it, too, involves synaptic plasticity.
Many clinicians and researchers say the field should move beyond a focus on neurotransmitters and look at activating entire neural circuits in the brain, networks of interconnected neurons that perform specific functions. Theres not one neurotransmitter, not one neural site where things go wrong, its some system-level dysfunction in the brain, said Cowen. A recent study analyzed patients with depression who underwent deep brain stimulation, in which electrodes are implanted to pass current through specific brain areas, or transcranial magnetic stimulation, which is a noninvasive form of stimulation. By looking at whether patients symptoms improved or worsened, researchers identified a brain circuit that includes the dorsolateral prefrontal cortex, an area that controls emotion processing and is impaired in patients with depression, that could be targeted to treat depression.
Understanding and treating depression could even go beyond the brain, as immune molecules such as cytokines that control inflammation could also be considered potential treatment targets. One analysis found that patients with depression had different levels of neuroinflammatory molecules in the blood. Other clues come from observing patients treated with medications that target inflammation for other conditions. Such studies found that patients treated with drugs that suppress immune activity, like those that target the molecule IL-6, had reduced depressive symptoms.
While the paradigms surrounding psychiatry seem to be shifting, new drugs and treatments still have a long road to approval and widespread use. The drug development pipeline has been particularly fruitless for psychiatry, which has a 6.2% likelihood of getting a drug from Phase 1 clinical trials to approval, as compared to infectious diseases treatments that have about 20% likelihood of approval.
Even if new treatments are approved, patients could encounter obstacles in accessing them, especially populations that already have poor access to mental health care due to high rates of poverty and lack of insurance, experts say. Many of the novel therapies are technically challenging to administer and require specialized facilities with trained professional staff. And many psychedelics are still classified as Schedule I drugs, as illegal as street drugs like heroin. Some, like ketamine, can be abused, and the long-term effects of chronic use of psychedelics are not clear, said Gerard Sanacora, psychiatrist and director of the Yale Depression Research Program.
A number of states have moved to relax laws governing use of psychedelics. In November 2020, Oregon became the first state to decriminalize possession and legalize therapeutic use of psilocybin, the active ingredient in magic mushrooms, and California may soon be next. In March of this year, a law decriminalizing magic mushrooms, ayahuasca, and mescaline went into effect in Washington, D.C. Recently, Rep. Alexandria Ocasio-Cortez (D-N.Y.) proposed an amendment to allow research into the therapeutic potential of Schedule I drugs like psilocybin and ecstasy.
The research and law changes are giving many patients a reason for optimism. Attardo is eager to try psilocybin, which data suggest could have a longer-lasting therapeutic effect than ketamine, whose benefits last just a few days for him. Just knowing that his depression can disappear, like when he is taking ketamine or during those first few months on Prozac, gives him hope: Im not trapped forever.
Go here to see the original:
- Psychedelics can change humanity for the better. Its time ... - January 9th, 2022
- 'Microdosers' of LSD and magic mushrooms are wiser... - Daily Maverick - January 9th, 2022
- Core One Labs Now Also Working to Biosynthesize DMT and Receives License - Financial Post - January 9th, 2022
- NeonMind to Present at H.C. Wainwright Bioconnect Conference - Yahoo Finance - January 9th, 2022
- Magic mushroom companies are on the Nasdaq now. Thats a recipe for a bad trip - The Guardian - January 7th, 2022
- Psilocybin therapy options could expand in Hawaii | Hawai'i Public Radio - Hawaiipublicradio - January 7th, 2022
- From psychedelics to 'The Great Resignation' - wellness trends for 2022 - CapeTown ETC - January 7th, 2022
- Ketamine, Psilocybin and the Rise of Missouri Psychedelics - Riverfront Times - December 25th, 2021
- Animals That Eat Psychedelics And Enjoy The Trip - Benzinga - Benzinga - December 25th, 2021
- Bad Hug - The Cut - December 25th, 2021
- How Seeing God Might Be The Secret To The Most Cutting-Edge Mental Health Treatments - Forbes - December 25th, 2021
- Happy Holidays From The Dales Report Team - The Dales Report - December 25th, 2021
- GOP Lawmakers File Bills To Streamline Research Into Marijuana, Psychedelics And Other Schedule I Drugs - Marijuana Moment - December 22nd, 2021
- Meet Zappy Zapolin, The Psychedelic Concierge Who Turned Lamar Odom On To Ketamine - Forbes - December 22nd, 2021
- Numinus Wellness inc: Leading in the psychedelics race - Proactive Investors UK - December 22nd, 2021
- When Aldous Huxley Opened the Doors of Perception - The MIT Press Reader - December 22nd, 2021
- Kratom Attracts Investor Attention After Regulatory Win - Bloomberg - December 22nd, 2021
- Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so... - December 22nd, 2021
- Revenge travel and psychedelic retreats: The travel trends taking flight in 2022 - AsiaOne - December 22nd, 2021
- Cybin Awarded Notice of Allowance from US Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety... - December 15th, 2021
- TGA blocks bid to have MDMA, magic mushrooms used to treat mental health conditions - ABC News - December 15th, 2021
- PharmaTher Announces Positive Research Results for LSD Microneedle Patch - Yahoo Finance - December 15th, 2021
- MDMA could soon be used to treat PTSD according to physicians - Mixmag - December 15th, 2021
- MindMed Appoints Robert Barrow as Chief Executive Officer and Director - Yahoo Finance - December 15th, 2021
- MAPS and Wesana Health Resume Negotiations - GlobeNewswire - December 15th, 2021
- Sex, psychedelics and murderous impulses: Do we know too much about Will Smith? - The Independent - November 7th, 2021
- PharmaDrug commissions TIBI for advancing psychedelics program with analogue DMT formulation to cure eye diseases - Proactive Investors USA - November 7th, 2021
- I Have $1,000. Should I Invest In Cannabis, Crypto Or Psychedelics? - Benzinga - Benzinga - November 7th, 2021
- Psychedelics Could Be New Frontier in End-of-Life Care - Hospice News - November 5th, 2021
- Detroit just decriminalized psychedelics and magic mushrooms. Heres what that means - PBS NewsHour - November 5th, 2021
- Psychedelics linked to lower risk of heart disease and diabetes - Medical News Today - November 5th, 2021
- The people turning to psychedelics on their deathbeds - The Independent - November 5th, 2021
- Psychedelic Therapy Is Hyped, But Its Not Risk-Free: How Therapy Abuse Can Retraumatize Clients - Forbes - November 5th, 2021
- Defeating Gambling Addiction: New Study Looks To Defy The Odds With Psychedelics - Forbes - November 5th, 2021
- This Psychedelics Unicorn's Stock Is Up 50% In One MonthBeating Bitcoin, Ethereum And Dogecoin - Benzing - Benzinga - November 5th, 2021
- This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop - Benzinga - November 5th, 2021
- Biglaw Associate Is Advocating For Therapeutic Use Of Psychedelics And The Firm Is Backing Him Up - Above the Law - November 5th, 2021
- Easthampton is the fourth city in Mass. to vote to decriminalize psychedelics - WBUR - October 24th, 2021
- There Could Be a Curious Link Between Psychedelics And Improved Heart Health - ScienceAlert - October 24th, 2021
- How Atai Is Transforming The Landscape Of Mental Health Using Psychedelics (Part 2) - Forbes - October 24th, 2021
- A recent history of therapeutic psychedelics - Toronto Life - October 24th, 2021
- New Research Hints at a Link Between Psychedelics and Improved Heart Health - The Swaddle - October 24th, 2021
- Why Ketamine-Assisted Therapy Has Gone Mainstream - Forbes - October 24th, 2021
- Ketamine and psilocybin, better known as party drugs, showing promise for treatment of mood disorders - CTV News - October 24th, 2021
- Recent progress in psychedelic therapies - Lexology - October 24th, 2021
- Miracles and medication: The new science of psychedelic drugs - Stuff.co.nz - October 24th, 2021
- UAB researcher granted federal funding for psilocybin and smoking study - The Mix - October 24th, 2021
- Yale researchers using psychedelics to find new treatments for depression - WTNH.com - September 17th, 2021
- Want Quick Exposure To The Psychedelics Sector? Check Out This New Active ETF - Benzinga - Benzinga - September 17th, 2021
- 5 things to know about the Ann Arbor psychedelic shroom fest - MLive.com - September 17th, 2021
- A Look At Psychedelics Stock PharmaTher And Its Recent Bull Run - Benzinga - Benzinga - September 17th, 2021
- Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) -... - September 17th, 2021
- Psychedelics research and public education elevated by multiple gifts - UC Berkeley - September 16th, 2021
- Pain Awareness Month: Psychable Educates Patients on Transformative Power of Using Psychedelics as Medicine for Pain Treatment, Management and Healing... - September 16th, 2021
- $80 Million Granted to Research Psychedelic Properties of Ingesting Toad Venom - Newsweek - September 16th, 2021
- Psychedelic Use on the Rise As Gen Z Seeks To Enhance Connectedness - VICE UK - September 16th, 2021
- Phyto Partners Cannabis VC on Why He's Investing in Psychedelics - Business Insider - September 16th, 2021
- Detroit Voters Will Decide On Psychedelics Decriminalization Ballot Measure In November - Marijuana Moment - September 16th, 2021
- Seattle bid to decriminalize psychedelics could have profound effect on treating addiction - MyNorthwest.com - September 16th, 2021
- Post-9/11 vets go to Mexico to treat trauma with psychedelic - The San Diego Union-Tribune - September 16th, 2021
- Lobe Sciences to Participate at the Advances in Me... | INN - Investing News Network - September 16th, 2021
- Seattle is now in the process of legalizing psychedelics, heres what to know - Curiocity - September 16th, 2021
- World Suicide Prevention Day: Suicide Remains a Leading Global Cause of Death; Communities Across the World Seek Expanded Use of Psychedelics as... - September 16th, 2021
- Psilocybin Transdermal Patches Could Be The Next Big Thing In Psychedelics - Forbes - September 1st, 2021
- Psychedelics are getting closer to approval, but the market may not be ready - FierceBiotech - August 22nd, 2021
- At-Home Genetic Testing Cant Tell You If Youre Going to Have a Bad Trip - VICE - August 22nd, 2021
- Past, Present & Future of Psychedelic-Assisted Therapy: A New Dawn for Mental Health and Neuroscience - cmc.edu - August 22nd, 2021
- When did humans start experimenting with alcohol and drugs? - EL PAS in English - August 22nd, 2021
- Origin Therapeutics Will Invest $5.1M In Psychedelics Startups - Yahoo Finance - August 14th, 2021
- GR is getting close to decriminalizing psychedelic plants and fungi - Fox17 - August 14th, 2021
- PsychedelicNewsBreaks Microdose Psychedelic Insights to Deep Dive into World of Psychedelic Medicine Investment at Upcoming Conference -... - August 14th, 2021
- Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use - PRNewswire - August 14th, 2021
- Neil deGrasse Tyson Talks Psychedelic Mushrooms And The Weird World Of Fungi On His Podcast - IFLScience - August 14th, 2021
- Delic Announces Luke Storey, Transformation Coach and Creator/Host of Thought-Provoking Podcast, The Life Stylist to Speak at Meet Delic: The World's... - August 14th, 2021
- Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast - StreetInsider.com - August 14th, 2021
- Cybin Inc. Announces 2021 First Quarter Financial Results and Business Highlights - Business Wire - August 14th, 2021
- Biomind Labs Files Patent Application in the United States Patent and Trademark Office, Its 4th Patent Application - Yahoo Finance - August 14th, 2021
- Researchers Concerned About Whitewashing of Psychedelic-Assisted Mental Health Research - Mad In America - James Moore - August 6th, 2021
- Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know - Yahoo Finance - August 6th, 2021
- Guide to the psychedelics industry: Companies, investors, science - Business Insider - August 6th, 2021